B
Bull
Bull · 25%SPRY
$57.15
Scenario price
$4.230
+0.221 (+5.22%)At close
Loading chart…
- High
- 4.320
- Open
- 4.070
- VWAP
- 4.18
- Volume
- 1.51M
- Mkt Cap
- 780.01M
- Low
- 4.000
- Amount
- 6.31M
- EV/EBITDA, TTM
- -1.73
ARS Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy, an epinephrine nasal spray indicated in the United States for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients who weigh 33 lbs. or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. neffy is an FDA and European Commission (EC)-approved needle-free epinephrine product, and also has approvals in the United Kingdom, Japan, Australia, and China. It is advancing its nasal spray development program across multiple Type I hypersensitivity reactions, including acute flares of urticaria.
AI analysis of ARS Pharmaceuticals Inc (SPRY)
HoldARS Pharmaceuticals Inc is not a good buy right now due to its current price of $4.02 being significantly lower than the analyst price targets of $15 and $30, indicating potential upside. However, the stock has a low RSI of 39.167, suggesting it may be oversold, but the recent 65.01% year-to-date decline raises concerns about its stability.
Valuation Metrics
The current forward P/E ratio for ARS Pharmaceuticals Inc (SPRY) is 0.00, compared to its 5-year average forward P/E of -11.44.
Alphio AI Price Scenarios for SPRY
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding SPRY
Events Timeline
News
7.010-02PRnewswireARS Pharmaceuticals Class Action Reminder
7.009-30PRnewswireARS Pharmaceuticals Faces Class Action Over CVS Caremark Coverage Delay
7.009-29PRnewswireARS Pharmaceuticals Class Action Reminder
7.009-24PRnewswireFaruqi & Faruqi Encourages ARS Investors to Reach Out
7.009-21PRnewswireARS Pharmaceuticals Class Action Notice Issued
SPRY FAQ — answered by Alphio AI
ARS Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy, an epinephrine nasal spray indicated in the United States for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients who weigh 33 lbs. or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. neffy is an FDA and European Commission (EC)-approved needle-free epinephrine product, and also has approvals in the United Kingdom, Japan, Australia, and China. It is advancing its nasal spray development program across multiple Type I hypersensitivity reactions, including acute flares of urticaria. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
ARS Pharmaceuticals Inc is not a good buy right now due to its current price of $4.02 being significantly lower than the analyst price targets of $15 and $30, indicating potential upside. However, the stock has a low RSI of 39.167, suggesting it may be oversold, but the recent 65.01% year-to-date decline raises concerns about its stability.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.